Amedeo Smart

Free Medical Literature Service


 

Amedeo

Bladder Cancer

  Free Subscription

Articles published in
J Clin Oncol
    December 2023
  1. HE W, Zeng S, Xu C
    Controversy Surrounding Bladder-Sparing Radical Dose Radiotherapy as an Alternative to Radical Cystectomy for Clinically Node-Positive Nonmetastatic Bladder Cancer.
    J Clin Oncol. 2023 Dec 5:JCO2301920. doi: 10.1200/JCO.23.01920.
    >> Share

    November 2023
  2. CATHOMAS R, Rothschild SI, Hayoz S, Bubendorf L, et al
    Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
    J Clin Oncol. 2023;41:5131-5139.
    >> Share

    October 2023
  3. KAMAT AM, Apolo AB, Babjuk M, Bivalacqua TJ, et al
    Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.
    J Clin Oncol. 2023 Oct 4:JCO2300307. doi: 10.1200/JCO.23.00307.
    >> Share

    September 2023
  4. SIEFKER-RADTKE AO, Cauley D, Alhalabi O
    Combinations, Sequencing, and the Contribution of Components: New Frontline Standards for Metastatic Urothelial Carcinoma.
    J Clin Oncol. 2023;41:4084-4086.
    >> Share

    August 2023
  5. VON DER MAASE H, Hansen SW, Roberts JT, Dogliotti L, et al
    Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.
    J Clin Oncol. 2023;41:3881-3890.
    >> Share

  6. SMALL EJ
    Flashback Foreword: Gemcitabine/Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Transitional Cell Carcinoma.
    J Clin Oncol. 2023;41:3879-3880.
    >> Share

  7. STEIN JP, Lieskovsky G, Cote R, Groshen S, et al
    Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients.
    J Clin Oncol. 2023;41:3772-3781.
    >> Share


  8. JCO Flashback: Long-Term Outcomes of Radical Cystectomy in Patients With Invasive Bladder Cancer (2001).
    J Clin Oncol. 2023;41:3771.
    >> Share

  9. BOSL GJ
    Flashback Foreword: Radical Cystectomy in the Treatment of Bladder Cancer.
    J Clin Oncol. 2023;41:3769-3770.
    >> Share

    July 2023
  10. SWINTON M, Mariam NBG, Tan JL, Murphy K, et al
    Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer.
    J Clin Oncol. 2023 Jul 21:JCO2300725. doi: 10.1200/JCO.23.00725.
    >> Share

  11. POWLES T, Park SH, Caserta C, Valderrama BP, et al
    Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After >/=2 Years of Follow-Up.
    J Clin Oncol. 2023;41:3486-3492.
    >> Share

    June 2023
  12. SARFATY M, Golkaram M, Funt SA, Al-Ahmadie H, et al
    Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.
    J Clin Oncol. 2023;41:3225-3235.
    >> Share

    March 2023
  13. COLEMAN JA, Yip W, Wong NC, Sjoberg DD, et al
    Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.
    J Clin Oncol. 2023;41:1618-1625.
    >> Share

    January 2023

  14. Erratum: DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
    J Clin Oncol. 2023 Jan 25:JCO2202889. doi: 10.1200/JCO.22.02889.
    >> Share

  15. STERNBERG CN, Petrylak DP, Bellmunt J, Nishiyama H, et al
    FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression.
    J Clin Oncol. 2023;41:629-639.
    >> Share

  16. SADEGHI S, Quinn D, Dorff T, Pal S, et al
    EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma.
    J Clin Oncol. 2023;41:640-650.
    >> Share

  17. PLIMACK ER, Zibelman MR
    Platinum-Free Systemic Therapy in First-Line Metastatic Urothelial Carcinoma: Mirage or Oasis in the Platinum Desert?
    J Clin Oncol. 2023;41:7-10.
    >> Share

  18. CRABB SJ, Hussain S, Soulis E, Hinsley S, et al
    A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.
    J Clin Oncol. 2023;41:54-64.
    >> Share

  19. ROSENBERG JE, Park SH, Kozlov V, Dao TV, et al
    Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
    J Clin Oncol. 2023;41:43-53.
    >> Share

    November 2022
  20. KIM SH, Lerner SP
    Risk Stratification of Nonmuscle Invasive Bladder Cancer and Innovative Approaches to Management of Ta Low-Grade Tumors.
    J Clin Oncol. 2022 Nov 30:JCO2202104. doi: 10.1200/JCO.22.02104.
    >> Share

    October 2022
  21. LINDGREN MS, Hansen E, Azawi N, Nielsen AM, et al
    DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
    J Clin Oncol. 2022 Oct 12:JCO2200470. doi: 10.1200/JCO.22.00470.
    >> Share

    August 2022
  22. ZHANG S
    Neoadjuvant Programmed Cell Death Protein 1 and Chemotherapy in Combination in Muscle-Invasive Urothelial Cancer: Promising, But Not Deserving to Try Further.
    J Clin Oncol. 2022;40:2656.
    >> Share

    July 2022
  23. GRIMM MO, Schmitz-Drager BJ, Zimmermann U, Grun CB, et al
    Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma.
    J Clin Oncol. 2022;40:2128-2137.
    >> Share

    June 2022
  24. ZENG S, Zhang Z, Xu C
    Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as the Gold Standard Neoadjuvant Chemotherapy Regimen for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer Remains Controversial.
    J Clin Oncol. 2022 Jun 15:JCO2200669. doi: 10.1200/JCO.22.00669.
    >> Share

    May 2022
  25. OWENS-WALTON J, Williams C, Rompre-Brodeur A, Pinto PA, et al
    Minority Enrollment in Phase II and III Clinical Trials in Urologic Oncology.
    J Clin Oncol. 2022;40:1583-1589.
    >> Share

    April 2022
  26. SONPAVDE GP, Mouw KW, Mossanen M
    Therapy for Muscle-Invasive Urothelial Carcinoma: Controversies and Dilemmas.
    J Clin Oncol. 2022;40:1275-1280.
    >> Share

    March 2022
  27. PFISTER C, Gravis G, Flechon A, Chevreau C, et al
    Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
    J Clin Oncol. 2022 Mar 7:JCO2102051. doi: 10.1200/JCO.21.02051.
    >> Share

    January 2022
  28. FUNT SA, Lattanzi M, Whiting K, Al-Ahmadie H, et al
    Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
    J Clin Oncol. 2022 Jan 28:JCO2101485. doi: 10.1200/JCO.21.01485.
    >> Share

    October 2021
  29. POWLES T, Petrylak DP, Rosenberg JE
    Beyond Chemotherapy and Checkpoint Inhibitors: Weighing the Risks and Benefits of the Novel Therapies for Metastatic Urothelial Carcinoma.
    J Clin Oncol. 2021;39:3411-3412.
    >> Share

    August 2021
  30. ROSE TL, Harrison MR, Deal AM, Ramalingam S, et al
    Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
    J Clin Oncol. 2021 Aug 24:JCO2101003. doi: 10.1200/JCO.21.01003.
    >> Share

  31. ROSENBERG JE, Ballman KA, Halabi S, Atherton PJ, et al
    Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
    J Clin Oncol. 2021;39:2486-2496.
    >> Share

    December 2020
  32. CATTO JWF, Gordon K, Collinson M, Poad H, et al
    Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study.
    J Clin Oncol. 2020 Dec 17:JCO2001665. doi: 10.1200/JCO.20.01665.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016